The abstract is read at the publisher; the summary is JClub's.
Anti-IL-10 autoantibodies are found in 26/1045 paediatric inflammatory bowel disease patients (2.5%), and are linked to more severe, difficult-to-treat disease.
- Why it matters: IL-10 helps maintain intestinal immune balance, but neutralising anti-IL-10 autoantibodies in paediatric IBD are incompletely characterized for prevalence and clinical phenotype.
- What they did: In a cross-sectional multicentre study across paediatric IBD cohorts from four countries, serum/plasma anti-IL-10 was tested and IL-10 neutralisation confirmed using functional IL-10 reporter assay, competitive ELISA, and cytokine release assays.
- The result: Anti-IL-10 positivity (IgG) amplified pro-inflammatory cytokine responses in vitro and associated with difficult-to-treat disease (23% vs 6%, p=0.03), acute severe UC (26% vs 6%; p=0.038), and colectomy (27% vs 6%, p=0.01), with 16/20 (80%) carrying HLA-DRB1*01:03.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.